Lupus (SLE)



Aurinia Renal Response in Active Lupus With Orelvo (Voclosporin)


Condition:   Lupus Nephritis
Interventions:   Drug: Voclosporin;   Drug: Placebo Oral Capsule
Sponsor:   Aurinia Pharmaceuticals Inc.
Recruiting - verified May 2017


Lupus and Observance


Condition:   Systemic Lupus, Skin Lupus
Intervention:   Biological: Hydroxychloroquine dosage
Sponsor:   University Hospital Center of Martinique
Not yet recruiting - verified January 2017


High Quality Evidence of Chinese Lupus Nephritis (HELP)


Condition:   Lupus Nephritis
Intervention:   Other: No Intervention
Sponsor:   Sun Yat-sen University
Recruiting - verified December 2016


The Effect of Metformin on Reducing Lupus Flares


Condition:   Systemic Lupus Erythematosus
Interventions:   Drug: metformin;   Drug: placebo
Sponsor:   RenJi Hospital
Recruiting - verified June 2016


Walk With Ease Program For Patients With Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Intervention:   Other: "Walk With Ease"
Sponsors:   University of North Carolina, Chapel Hill;   North Carolina Translational and Clinical Sciences Institute
Recruiting - verified April 2017


Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis


Condition:   Lupus Nephritis
Interventions:   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
Sponsor:   The University of Hong Kong
Recruiting - verified October 2016


Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis


Condition:   Lupus Nephritis
Interventions:   Biological: Anifrolumab;   Drug: Placebo
Sponsors:   AstraZeneca;   Parexel
Recruiting - verified February 2017


Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus


Condition:   Systemic Lupus Erythematosus
Interventions:   Drug: Brentuximab vedotin;   Drug: Placebo
Sponsor:   Seattle Genetics, Inc.
Recruiting - verified September 2016


Development of a Novel Glutamate Receptor Ligand for PET Scans in Neuropsychiatric Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Intervention:  
Sponsor:   Northwell Health
Recruiting - verified January 2017


Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Interventions:   Drug: ACT-334441;   Drug: Placebo
Sponsor:   Actelion
Completed - verified March 2017


Lupus Flares and Histological Renal Activity at the End of the Treatment (LuFla)


Condition:   Lupus Nephritis
Intervention:   Procedure: Renal Biopsy
Sponsor:   Hospital de Clinicas José de San Martín
Active, not recruiting - verified September 2016


Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients


Condition:   Systemic Lupus Erythematosus
Interventions:   Drug: MT-1303 Low dose;   Drug: MT-1303 High dose
Sponsor:   Mitsubishi Tanabe Pharma Corporation
Active, not recruiting - verified January 2017


A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.


Condition:   Systemic Lupus Erythematosus
Interventions:   Drug: CC-220;   Drug: CC-220;   Drug: CC-220;   Drug: CC-220;   Drug: Placebo
Sponsor:   Celgene
Active, not recruiting - verified May 2017


Nelfinavir in Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Intervention:   Drug: Nelfinavir
Sponsors:   Northwell Health;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified January 2017


Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions


Conditions:   Lupus Erythematosus, Discoid;   Lupus Erythematosus, Systemic
Interventions:   Drug: R932333;   Drug: Placebo
Sponsor:   Rigel Pharmaceuticals
Completed - verified June 2016


Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus


Condition:   Cutaneous Lupus Erythematosus
Intervention:  
Sponsor:   University of Pennsylvania
Recruiting - verified October 2016


Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus


Condition:   Subacute Cutaneous Lupus Erythematosus
Interventions:   Drug: KRP203 - 1.2mg;   Drug: Placebo to KRP203 - 1.2 mg
Sponsor:   Novartis Pharmaceuticals
Completed - verified March 2017


A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Patients With Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Intervention:   Drug: Lupuzor
Sponsor:   Cephalon
Terminated - verified July 2016


A Study to Evaluate the Efficacy and Safety of CEP-33457 in Patients With Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Interventions:   Drug: Lupuzor;   Drug: Placebo
Sponsor:   Cephalon
Completed - verified July 2016


Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis


Condition:   Lupus Nephritis
Intervention:   Drug: NKT-01
Sponsor:   Nippon Kayaku Co.,Ltd.
Completed - verified July 2008


A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02


Condition:   Systemic Lupus Erythematosus
Intervention:   Biological: Belimumab
Sponsors:   Human Genome Sciences Inc., a GSK Company;   GlaxoSmithKline
Completed - verified January 2017


Duke Lupus Registry


Conditions:   Systemic Lupus Erythematosus;   Cutaneous Lupus
Intervention:  
Sponsor:   Duke University
Recruiting - verified November 2016


Vitamin D Therapy in Patients With Systemic Lupus Erythematosus (SLE)


Condition:   Systemic Lupus Erythematosus
Interventions:   Drug: Cholecalciferol;   Drug: Cholecalciferol;   Drug: Cholecalciferol
Sponsors:   Medical University of South Carolina;   American College of Rheumatology Research and Education Foundation;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Completed - verified August 2016


A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970g


Condition:   Lupus Nephritis
Intervention:   Drug: Rituximab
Sponsor:   Genentech, Inc.
Withdrawn - verified April 2017


Cyclophosphamide and rATG/Rituximab in Patients With Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Intervention:   Biological: Hematopoietic stem cell transplantation
Sponsor:   Northwestern University
Active, not recruiting - verified January 2017

Refine Your Search Advanced Search